Avalo Therapeutics (AVTX) Share-based Compensation (2014 - 2026)

Avalo Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $779000.0 for Q1 2026.

• Quarterly Share-based Compensation changed N/A year-over-year to $779000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 304.93% YoY) and the FY2025 annual result came in at $510000.0, changed N/A from the prior year.
• Share-based Compensation was $779000.0 for Q1 2026 at Avalo Therapeutics, up from -$8.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $8.6 million in Q3 2025 and bottomed at -$8.6 million in Q4 2025.
• A 5-year average of $880000.0 and a median of $777500.0 in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation jumped 266.85% — and 2024, when it plunged 170.44%.
• Avalo Therapeutics' Share-based Compensation stood at $843000.0 in 2022, then dropped by 7.95% to $776000.0 in 2023, then slumped by 181.06% to -$629000.0 in 2024, then tumbled by 1267.73% to -$8.6 million in 2025, then soared by 109.05% to $779000.0 in 2026.
• Business Quant data shows AVTX's Share-based Compensation at $779000.0 in Q1 2026, -$8.6 million in Q4 2025, and $8.6 million in Q3 2025.